- Home
- ICCM vs IGMS Comparison
ICCM vs IGMS Comparison
Compare ICCM & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- IGMS
- Stock Information
- Founded
- ICCM 2006
- IGMS 1993
- Country
- ICCM Israel
- IGMS United States
- Employees
- ICCM N/A
- IGMS N/A
- Industry
- ICCM
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ICCM
- IGMS Health Care
- Exchange
- ICCM Nasdaq
- IGMS Nasdaq
- Market Cap
- ICCM 74.7M
- IGMS 82.1M
- IPO Year
- ICCM N/A
- IGMS 2019
- Fundamental
- Price
- ICCM $1.11
- IGMS $1.24
- Analyst Decision
- ICCM Strong Buy
- IGMS Hold
- Analyst Count
- ICCM 1
- IGMS 8
- Target Price
- ICCM $2.50
- IGMS $6.14
- AVG Volume (30 Days)
- ICCM 352.8K
- IGMS 198.4K
- Earning Date
- ICCM 03-27-2025
- IGMS 03-06-2025
- Dividend Yield
- ICCM N/A
- IGMS N/A
- EPS Growth
- ICCM N/A
- IGMS N/A
- EPS
- ICCM N/A
- IGMS N/A
- Revenue
- ICCM $3,291,000.00
- IGMS $2,679,000.00
- Revenue This Year
- ICCM $75.63
- IGMS $134.71
- Revenue Next Year
- ICCM $69.36
- IGMS $74.27
- P/E Ratio
- ICCM N/A
- IGMS N/A
- Revenue Growth
- ICCM 1.92
- IGMS 25.77
- 52 Week Low
- ICCM $0.48
- IGMS $1.15
- 52 Week High
- ICCM $1.66
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ICCM 35.03
- IGMS 37.38
- Support Level
- ICCM $1.04
- IGMS $1.17
- Resistance Level
- ICCM $1.25
- IGMS $1.31
- Average True Range (ATR)
- ICCM 0.09
- IGMS 0.09
- MACD
- ICCM -0.04
- IGMS 0.05
- Stochastic Oscillator
- ICCM 14.29
- IGMS 32.14
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.